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        An Afghan migrant who had returned from a visit to the 
Middle East 2 years before was seen with a non-healing 
painless lesion on the forearm (  Figure 1A    ). A skin biopsy 
showed intracellular   Leishmania   parasites in the subcu-
tis (  Figure 1B and C  ), and the polymerase chain reaction 
(PCR) was positive for   Leishmania tropica  . At the same 
time, a German traveler who had returned from a vacation 
to Central America 1 month before was seen with progres-
sively ulcerating painless lesions on the ankle, thigh, and 
forearm (  Figure 2A    ). Scarification of the lesions’ margins 
showed sparse   Leishmania   amastigotes (  Figure 2B and C  ) 
and the PCR from biopsies was positive for   L .   braziliensis . A 
28-day treatment with oral miltefosine (2 mg and 2.5 mg/kg, 
respectively) was initiated in both individuals and the patients 
were seen at intervals of several weeks (  Figures 3     and   4    ). 
All lesions healed, but both patients developed nausea and 
elevated liver function tests during pharmacotherapy. The 
highest values of aspartate aminotransferase (AST) and ala-
nine aminotransferase (ALT) were 66 U/L and 44 U/L in the 
female migrant and 73 U/L and 33 U/L in the male traveler, 
respectively  . Bilirubin levels were normal in both patients, 
  Figure   1.       Cutaneous Old World leishmaniasis caused by   Leish-
mania tropica   in an Afghan woman.   A  , Initial presentation of the dry, 
plaque-like lesion with central nodule on the forearm.   B ,  Intracellular 
parasites in vacuoles of a giant cell (arrowheads). Haematoxylin and 
eosin stain, magnification ×1,000.   C ,   Leishmania   in macrophages 
(arrowheads). Haematoxylin and eosin stain, magnification ×1,000. 
This figure appears in color at   www.ajtmh.org  .       
  Figure   2.        Cutaneous New World leishmaniasis caused by 
  Leish mania  braziliensis   in a German traveler after a vacation in 
Costa Rica and Belize.   A  , Initial presentation of the wet ulcer-
ated lesion on the ankle (upper row), thigh (middle row), and 
forearm (lower row). Lesions were superinfected with Panton 
Valentine leukocidin-negative   Staphylococcus aureus ,   Escheri-
chia coli  , and viridans streptococci.   B  , Extracellular   Leishmania  
amastigote in tissue scarification. Giemsa stain, magnification 
×1,000.   C  , Intracellular parasite in a monocyte (arrowhead). 
Giemsa stain, magnification ×1,000. This figure appears in color 
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but the male patient developed γGT levels of 113 U/L. All 
values returned to normal 2 and 3 weeks after the end of 
treatment, respectively. Neither patient’s lesions showed 
clinical relapse when examined 4 months after the end of 
therapy. Miltefosine (hexadecylphosphocholine) has been 
shown to be effective in cutaneous and visceral leishmania-
sis.  1   At least some strains of   L. braziliensis  , a species that 
can cause both cutaneous and mucocutaneous disease in the 
New World, have demonstrated a decreased sensitivity to 
the drug   in vitro ,  however. 2  
  Figure   3.       Follow-up presentation of Old World cutaneous leishmaniasis.   A  , Increasing local inflammation 14 days after start of miltefosine 
treatment. The lesion looks more nodular than before treatment.   B  , Decreasing inflammation 21 days after start of pharmacotherapy.   C ,  Resolution 
of lesion 4 weeks after the end of treatment. Repeated   Leishmania   serology remained negative throughout the observation period in this patient. 
This figure appears in color at   www.ajtmh.org  .       
  Figure   4.       Follow-up presentation of New World cutaneous leishmaniasis.   A  , Inflammatory accentuation of the lesions’ ring walls 
2 weeks after start of miltefosine treatment.   B  , Wounds are nearly fully covered by scar tissue 3 weeks after cessation of miltefosine ther-
apy.   C  , Resolution of lesions 7 weeks after the end of treatment. Upper row, lesion on the ankle; middle row, lesion on the thigh; lower 
row, lesion on the forearm.   Leishmania   immunoblot was positive in this patient at initial presentation. This figure appears in color at 
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